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Chlamydia trachomatis is the most common sexually 
transmitted bacterial infection (STI) in the world.1 Being 
a gram-negative, obligate intracellular parasitic pathogen, 
three out of the nine existing strains infect humans (C. 
trachomatis, C. pneumoniae, and C. psittaci), of which C. 
trachomatis is the most prominent. With a global 
prevalence of 4.2% in women and 2.7% in men, C. 
trachomatis infections have tremendous health and 
societal impact.2 With the bacterial STI being largely 
asymptomatic 70-90% of woman and 30-50% of men 
never display acute symptoms. However, infections can 
lead to substantial health damage before they are first 
noticed. Especially women are unaware of their status, so 
a statement of global rates is likely to be an 
underestimation.3 The high and increasing infection rates 
of C. trachomatis are accompanied by increasing costs to 
both health systems and individuals. Previous cost-
analysis studies have shown that the total direct lifetime 
cost of chlamydia is around half a billion US dollars in all 
those diagnosed and seeking treatment, representing 
about one-third of the $15.6 billion global direct lifetime 
cost spent on all STIs.1 Though widespread screening, 
adequate treatment, and various prevention programs 
have been helpful in increasing awareness and improving 
screening rates for chlamydia, these methods have not yet 
been able to reverse the rising trend of infections. Over 
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the years, rates of reported infections have increased 
almost tenfold, from 35 cases per 100,000 in 1986, to 332 
per 100,000 in 2005.4 These numbers clearly show that 
something must be done to slow or ideally stop the 
growing rates, manage negative consequences, and 
prevent possible antibiotic resistance.  
While persistence of the chlamydia bacterium has already 
been documented antibiotic resistance has not yet 
emerged in the pathogenesis of C. trachomatis to 
humans, but research does suggest that resistant 
phenotypes may arise in the future, especially with 
steadily increasing rates of infection.5,6 
In order to stop rising infection rates of a largely 
asymptomatic infection, and to control the potential of 
antibiotic resistance, vaccine development is essential.7,8 
Indeed, the WHO, UNICEF and GAVI have identified C. 
trachomatis as one of four STIs with the greatest 
potential for the vaccine market.1,4,5 Computer modelling 
and prediction analysis showed that even a partially 
protective vaccine in a sub-optimal vaccination program 
would decrease infections, morbidity, and associated 
costs of the disease, and a fully protective vaccine has the 
potential to eradicate chlamydia within 20 years.1,9  
The need for a C. trachomatis vaccine has long been 
recognized but unsuccessful human trials, of a whole-cell 
vaccine in the 1960s, caused a pause in the research field 
for many years.3 Over the last decades vaccine 
innovations for men were unsuccessful in contrast to 
flourishing veterinary vaccine innovations. Currently 
there are multiple commercially available veterinary 
vaccines against certain veterinary strains of chlamydia. 
While veterinary vaccines have different characteristics 
and developmental requirements than human vaccines, 
such developments suggest that the production of a 
human vaccine is possible.10 
To ensure a well-facilitated development process, a 
clearly defined market is considered crucial.11 However, 
to date there is no clear understanding of where 
innovators perceive the largest market opportunities to 
lie.12 Moreover, lack of a clear overview of vaccines and 
technologies in development hampers new innovators to 
join in a concerted effort to realize solutions to public 
health unmet needs.  
The main objective of this study is therefore to present an 
overview of the current state of chlamydia vaccine 
development by constructing and analyzing a dataset 
containing data from patent documents, literature and 
clinical trials. Patent analysis as a tool is used to assess 
markets, can inform manufacturers of their abilities to 
participate in vaccine markets and elucidates concerns 
surrounding new patent claims.13,14 
This study provides an overview of the development of a 
human chlamydia vaccine over the past 20 years and an 
overview of the involvement of different stakeholders 
(science, industry and government) in the vaccine 
development process. 
METHODS 
A comprehensive overview of chlamydia innovation 
efforts was obtained by studying patents and patent 
applications. Patent applications are measures of output 
of early-stage research. Most inventions in the 
pharmaceutical sector are covered by patents as they are 
the only way of offering solid intellectual property 
protection of new pharmaceutical compounds.15 Clinical 
trials represent late‐stage drug development that all new 
inventions must pass before market entry, which make 
clinical trials a reliable indicator of the short-term market 
entry. However, a significant share of inventions 
disclosed in patents will not enter clinical testing due to 
disappointing research results, or due to strategic 
reasons.16 By combining patent data for insight into the 
medium to long‐term interventions and clinical trial data 
for insight into the short‐term market entry this study 
provides an overview of the process of vaccine 
development for chlamydia diseases. 
Patents  
Data collection and selection 
The purpose of the patent analysis was to assess the 
trends and advances in chlamydia vaccine development 
in the last twenty years (1999-2019) in order to identify 
technologies and market changes that are supportive to 
the advancements in the field.  
Data for the patent analysis were taken from the 
European Patent Office (EPO) Espacenet database, 
containing over 90 million patents and widely considered 
a comprehensive database.17 Data were extracted under 
the guidance of an expert from the Dutch 
(governemental) Patent Office (Dutch RVO). Search 
criteria were developed using the cooperative patent 
classification (CPC) system, a bilateral system developed 
together by the EPO and the United States Patent and 
Trademark Office (USPTO), combining classification 
terms used by both offices. Using the CPC system as a 
search tool, all technological fields related to chlamydia 
vaccine development could be identified and used to 
search relevant patents.  
CPC codes were combined with specific search terms 
determined via expert guidance and initial database 
scoping. Based on the information desired, CPC code sets 
were chosen to find patents for two data sets - human 
vaccines and veterinary vaccines. After choosing relevant 
and comprehensive CPC codes, the advanced search 
option was used to combine codes with keywords 
retrieved from the literature to narrow our search. These 
were paired to codes through the use of Boolean 
operators, as visualized in Table 1. 
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Table 1: CPC codes and keyword combinations. 
Human  Results Animal Results 
A61K39/118 + chlamyd* + 
vaccin*/immun* 
224 A61K2039/552 + chlamyd* + vaccin*/immun* 6 
Chlamyd* + vaccin*/immun* 455 Y10S424 + chalmyd* + vaccin*/immun* 6 
A61K39/00 + chlamyd* + 
vaccin*/immun* 
176 
C07K14/295 + chlamyd* + vaccin*/immun* + 
NOT human 
152 
C07K14/295 + chlamyd* + 
vaccin*/immun* 
168 - - 
Total 1024 Total 404 
Total after deduplication  484 Total after deduplication 359 
Total animal + human 843 - - 
Total after deduplication 546 - - 
Total after all exclusion criteria applied 189 - - 
 
Data were exported as one comprehensive group to 
Microsoft Excel for deduplication and primary analysis. 
After deduplication and condensing based on priority 
numbers, 546 patents remained. Further exclusion criteria 
included exclusion of patents containing the words: 
“immunoassay”. “diagnosis”, “detection”, “treatment” in 
the title or abstract without also including “prevention”; 
exclusion of patents referring to Chlamydomonas, which 
is a genus of green algae; and exclusion of patents filed 
more than 20 years ago. Applying exclusion criteria 
resulted in 242 patents to analyze. Finally, after all 
remaining patents were imported into Atlas TI to be 
qualitatively analyzed, full text analysis of the patents led 
to a final exclusion of 53 additional patents and a final 
list of 189 patents for analysis.  
The final list of 189 patents was further analyzed to 
visualize time and geographical trends. In line with 
criteria for asssessing quantity over quality 15, we also 
looked into high quality patents, here defined as being 
cited more times.  
Through qualitative analysis of the patent text in Atlas TI, 
patents were placed in one of two categories: for 
veterinary use or for human use, based on the strain of 
chlamydia referred to and whether the patent text stated 
humans or animals to be the intended recipient of the 
innovation. Patents that mentioned both target groups 
were considered as human use.  
Subjecting the primary patent documents to a full text 
analysis, factors including bacterial strain, technological 
innovation, and applicant type (e.g. academia, 
individuals, government or company) were identified. 
Applicants mentioned as inventors were classified as 
such, and when mentioned in combination with the 
institutions they were classified as type of the institution. 
Specifically, for the timeline depictions a subset of data 
was created by excluding patents published in 2019 and 
2018 since due to an 18-month delay that occurs between 
patent filing and publication date this subset could not be 
considered complete. This resulted in excluding 10 
patents for this analysis and a final count of 179 patents, 
of which 34 patents were intended for veterinary use, and 
145 patents intended for human use. 
Starting from the priority documents, kind codes from all 
published patent documents in the same family were 
analyzed to identify the geographical territories in which 
patent protection was applied for per invention. Countries 
were then categorized based on the region they belonged 
to, resulting in the total number of applied and granted 
patents for the following regions: USA, Canada, South 
America, Europe, Ukraine and Turkey, Africa, Middle 
East, Russia and Oceania. In addition, patents applied for 
at the EPO, the WIPO, or Eurasian patent applications 
were listed separately.  
Clinical trial analysis 
To gain a full picture of the current market of human 
chlamydia vaccines, a clinical trial analysis was 
conducted to reveal relevant vaccines that may soon 
reach the market. The WHO’s International Clinical 
Trial’s Registry Platform (ICTRP) database and the U.S. 
National Library of Medicine’s (NLM) database were 
used to search clinical trials. While the ICTRP database 
shows active clinical trials, the NLM’s database allows 
the search of completed clinical trials, painting a full 
picture of the research field. Two search queries were 
used, ‘chlamydia vaccine,’ and ‘chlamydia’, which, after 
excluding all trials not related to chlamydia vaccinology, 
resulted in a total of three human clinical trials to be 
assessed. 
RESULTS 
Patent analysis overview 
From the 189 patents that were imported from Espacenet 
and analyzed in Excel and Atlas TI, 179 were used for 
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timelines to visualize trends in patent publication in the 
period 1999- 2017. The patent publication timeline 
(Figure 1) shows that the number of new patents for both 
human and veterinary patents remains fairly constant, 
although more patents are applied for human than for 
veterinary purposes. 
 
Figure 1: The US, Asia and Europe were considered most interesting ‘geographical’ territories for filing patent 
applications. Both human and veterinary patents show a modest but steady incline in number. 
 
Figure 2: The US outperforms applicants from other regions by a factor 3 in patent applications. Patent applicants 
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Between 1999 and 2017 most patents were applied for in 
the US, followed by Asia and Europe. 
Applicants  
The most patents were applied for by US applicants, 
followed by Asian and Russian applicants (Figure 2). 
These results suggest that North America is the most 
important player in new research towards the 
development of a chlamydia vaccine. 
Further analysis of the patent applicants identified the 
institutes, companies and individuals that applied for the 
patents. After companies, academia claimed the next 
greatest number of patent applications, followed by 
individual inventors (Figure 3). 
 
Figure 3: Companies form the largest group of 
applicants followed by academia. Patent applicants 
are shown per different applicant group (for total 
data set; 189 patents). 
 
Figure 4: Sanofi and Novartis/GSK are the major 
companies filing one third of patents for human use 
followed by academia and individuals. 
Major companies filed roughly one third of the total 
number of patents intended for human use, with Sanofi 
Pasteur owning the largest number of 30 patents, 
followed by Novartis/GlaxoSmithKline (GSK) owning 
14 patents and Emergent Biosciences with 5 patents 
(Figure 4). 
The qualitative analysis of patent content divided the 
patent documents into groups based on the strain of 
chlamydia they focused on (Figure 5). While a number of 
patent documents cited being pertinent to multiple 
chlamydia strains, the majority of patent documents 
intended for human use were only applicable to one of 
the two most relevant human strains: C. pneumoniae and 
C. trachomatis. 
Patent applications specifically for C. trachomatis strain 
vaccines (Figure 5A) are the leading strain over the years, 
while patent applications for C. pneumoniae have slowed 
down. Since 2014, there have been no new applications 
for patents specifically intended for this strain. 
Between 2001-2002 and 2004-2005 there was a small 
increase visible in patent filings intended for human use, 
applied for by Sanofi. Further analysis on these patents 
identified that primary scientists, with known 
collaborations to specific industry partners, have been 
prolific in these periods. The group of Murdin, in some 
instances collaborating with Sanofi, filed 22 patents in 
these periods and the group of Ratti, in some instances 
collaborating with Novartis, applied for 2 patents. An 
additional notable increase occurs in 2013, but very few 
of these patents are related to each other through 
inventors or applicants, suggesting distinct research 
efforts. 
Of these two particular groups of scientists the group of 
Murdin, filed in total 42 patents in the field between the 
years of 2000 and 2010, 27 of which in partnership with 
Sanofi Pasteur. The other group of applicants being the 
group of Ratti, was found to hold 9 similar patents 
between 2001 and 2005, in partnership with GSK. No 
recorded intentions of vaccine trials based on these 
patents were found.  
Of the 36 patent documents intended for veterinary use, 
the most common strains were C. psittaci and C. felis. 
(Figure 5B). In recent years, interest in patents for 
veterinary use declined significantly. Patent applications 
for C. abortus and C. trachomatis showed relatively large 
increases, though these were still small in absolute size. 
Technology 
Further qualitative analysis categorized technological 
features and vaccine components described in the patent 
documents. Most patent documents that were intended for 
human use described subunit vaccines (70 patents) and an 
additional 19 patent documents described subunit 
vaccines that made use of the major outer membrane 
protein (MOMP) antigen (Figure 6A). Only 2 patents 
referred to whole-cell vaccines, none of which were filed 
after 2005. Within the category ‘other’, we found patent 
documents using recombinant, chimeric and other 
vaccine preparation techniques. Only four patents were 
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Figure 5: Most relevant strain in human patents is (A) C. trachomatis and for veterinary patents; (B) C. psittaci                     
shown as cumulative publication trends for human and veterinary strains. 
  
Figure 5 (A and B): Subunit and MOMP vaccines are the most prevalent technologies in patents for human use. In 
patents for veterinary most used technology is the (inactive) whole-cell. Most relevant technologies are shown in 
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Table 2: Overview clinical trials in human. 
Name of trial Dates of activity Sponsor Collaborator Status  
Safety of chlamydia vaccine 
CTH522 in healthy women aged 18 






July 2016 –  








Safety and immunogenicity of a 
chlamydia vaccine CTH522  
{NCT03926728} 







C. trachomatis immunology and 
vaccinology study  
{NCT01150747} 
 






National Institute of 




In the patent documents intended for veterinary use only 
1 patent document from 2006 describes the use of a live 
antigen. Nearly half of all veterinary patent documents 
described the use of inactivated, whole-cell vaccines 
(Figure 6B). 
Breakthroughs in patents 
Two patents were cited more than 50 times. The first 
patent described a genomic sequence of C. pneumoniae, 
granted in 1999, and was cited in other patents 207 times 
since then. The other patent is for a MOMP vaccine, 
applied for by the US Department of Health in 1999. 
Human clinical trials  
Only three clinical trials were found for analysis. Two of 
the three trials focused on the same vaccine candidate and 
took place in the UK (Table 2). These trials made use of 
inventions described in patent documents applied for by 
the Statens Serum Institute, who is also the sponsor of the 
trials.  
The third clinical trial was intended to determine the 
protective T cell response to incidental trachoma 
infections, so as to understand how the body deals with 
incidental infection, and how the body may respond upon 
secondary infection. This clinical trial took place in the 
US.  
DISCUSSION 
This study presents an overview of the current state of the 
global chlamydia vaccine developments. By comparing 
inventions for chlamydia vaccines for both human and 
veterinary indications, we demonstrate the difference 
between and independence of both fields. The extensive 
patenting in the US points to this territory as most 
interesting for the development of a human chlamydia 
vaccine, specifically for the C. trachomatis strain. We 
conclude that chlamydia research is prolific but has to 
date been incapable of solving a significant unmet 
medical need. Recent breakthrough progressions, 
however, enabled by public-private partnerships, show 
promise for the future.  
Chlamydia infections have been epidemic since the early 
80’s.20 Despite the many efforts to lower the rate of 
(re)infections through e.g. early detection, treatment and 
prevention for repeat infections, C. trachomatis infections 
are rising.21 The ongoing unmet need and ‘mounting 
pressure’ to develop chlamydia vaccines is visible in the 
patent landscape and is especially reflected in patenting 
activity for interventions in humans.22 
This study found clear technical and clinical differences 
between innovation efforts in the human and veterinary 
field. For humans, the early days developed whole-cell 
vaccines with poor potential to enhance immune response 
or even resulted in disease enhancement, led to 
abandonment of this path.20 In contrast, nowadays the 
veterinary field is still depending on this technology 
which is in line with earlier findings.6,23 
Although the global burden for humans infections of C. 
trachomatis and C. pneumonia has not been well defined, 
68 million chlamydia infections are estimated to occur 
globally each year.1,24 Our data show that half of the 
human patent documents are intended for the 
development of vaccines for C. trachomatis and for C. 
pneumoniae as attempt to solve the growing unmet need. 
Of the six chlamydial strains that are associated with high 
morbidities in animals we show that half of all veterinary 
patents are intended for the prevention of C. psittaci and 
C. felis. This difference in focus on different strains 
suggests no connection between the two fields. Some of 
these animal pathogens however have been recognized as 
zoonotic agents and the presence of animal C. 
pneumoniae genotypes in humans suggest a potential 
cross-species transmission to humans. One of the other 
genotypes, C. psittaci, is an important causative agent of 
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widespread zoonotic psittacosis or parrot fever.25 Unmet 
needs will further extend when the veterinary chlamydia 
strains become a more global health problem in case of 
zoonoses and antibiotic resistance.  
We show here that the US represents the country with the 
most patent applications for human use applied by 
academia and individual scientist, some in cooperation 
with the industry (SANOFI/Pasteur and GSK). All this 
indicates a high interest or high sense of urgency to solve 
the unmet need in the US.21 In contrast, most veterinary 
vaccines are applied for by Chinese and Russian 
applicants. This interest by Chinese applicants can be 
explained by the economic burden that veterinary 
chlamydia serovars pose on Chinese livestock. In contrast 
to Western countries, China often uses herbal medicine as 
prophylaxis or in conjunction with antibiotic treatment 
which is less likely to be accepted in the global 
market.26,27  
Looking at institutional background, the majority of 
applicants on veterinary patents are academic, indicating 
the existence of barriers hampering the realization and 
transition of an innovation into clinical and business 
development.28 
Overcoming these barrier will become of more interest if 
and when the zoonotic potential of different chlamydia 
strains is revealed, as was the case for avian C. 
psittaci.25,29 When it comes to preventing the widespread 
issue of antibiotic resistance, both possible and expected 
with the chlamydia bacterium, innovations in the 
veterinary domain are going to be highly relevant.26,27  
In contrast to the dominance of academia in patents for 
veterinary use, a large majority of patents for human use 
are filed by major pharmaceutical companies, especially 
ones known for the production of successful vaccines, 
namely Sanofi Pasteur and GSK. This supports the 
perceived commercial relevance of human veterinary 
vaccines.30 Interestingly, the group of Murdin, affiliated 
with Sanofi Pasteur, is the applicant of the majority of 
patents intended for human use. With 42 patents in total, 
pertaining to C. trachomatis, C. pneumoniae, and to 
multiple strains, the group’s presence demonstrates their 
leadership in the field. Additionally, their affiliation with 
Sanofi Pasteur underlines the importance of Sanofi 
Pasteur as an investor in the field. A second group of 
researchers surrounding Guilio and affiliated with GSK, 
also holds a large number of patents, again for both 
human C. pneumoniae and C. trachomatis strains. This 
ownership indicates the similar interest of GSK in the 
field. Considering these patents have been filed more 
recently, it is of interest to see whether these inventions 
will translate in new medical interventions that are to be 
tested in clinical trials in the coming years.  
Over time, inventions on the two most important strains 
for human use, C. trachomatis and C. pneumoniae, have 
increased in number. The timelines overview in figure 5A 
however shows a plateau has been reached in the 
innovation-curve for C. pneumoniae suggesting 
saturation or declining interest in contrast to the C. 
trachomatis research.31,32 Even though the high global 
antibody prevalence for C. pneumoniae is increasing 
proportionately and known to be associated with the 
onset of reactive arthritis and asthma.25 
Up to now a large number of preclinical chlamydia 
vaccine trials have taken place in mouse and non-human 
primate model systems.22 Recent progress in clinical 
development has been booked by a public-private 
partnership, although the first human clinical trials are 
still in phase I, suggesting a successful step in vaccine 
development. Interestingly, despite active patenting 
activity in the US, this clinical trial was conducted in 
Europe.18 The patents underlying the medical intervention 
were filed in different territories, including the US, Japan 
and China, supporting the global nature of this unmet 
need. Based on our analysis we conclude that this public-
private partnership has been instrumental in establishing 
breakthrough progression; the Staten Serum Inst. working 
together with Imperial College London for the first 
human clinical trial in 2018. 
The gap in the human chlamydia vaccine development 
process compared to veterinary vaccine development 
leads to the assumption that in human chlamydia vaccine 
development different barriers play a role limiting the 
innovation. One significant barrier was to generate an 
immune mechanism of protection against mucosal 
infections.33 After the sequence of C. pneumoniae and the 
sequence for the MOMP vaccine were described in two – 
highly cited – patents, a large number of patent 
documents described subunit-vaccine technology 
including the MOMP technology solving the barrier of 
the induction of an immune reaction.34 Being one of the 
first antigen molecules described, the MOMP subunit has 
been the subject of many innovation efforts.35 More 
recent patenting developments primarily focus on subunit 
vaccines and may use MOMP immunogenic technology, 
even though vaccination attempts with MOMP subunits 
have delivered variable results.34 
Currently, there is debate in the academic literature 
whether it would be feasible to develop one vaccine that 
targets multiple serovars.36 Since the MOMP technique is 
used to differentiate the chlamydia serovars, there are two 
specific serovars of interest in C. trachomatis for the 
development of a cross-serovar vaccine. The first causes 
genital chlamydia infection, and the second ocular 
infection, trachoma but are similar in pathology and 
affecting the immune system.37-39  
An effective human chlamydial vaccine would have 
public health benefits in both HICs and LMICs. The 
greatest benefits will be in LMIC settings, where lack of 
medical infrastructure and resources preclude chlamydia 
screening programs and the disease burden is high.24 
Public-private partnerships with NGOs will be vital in 
introducing a vaccine that will be successful in reducing 
disease burden and preventing trachoma-related blindness 
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in LMICs. Especially because of the 10 patents 
applications for the region Africa, we suggest that 
partnerships should focus on the development of a 
vaccine that is applicable to both serovars preventing 
genital and ocular infections. 
For the interpretation of the findings of this study several 
limitations need be taken into account. First, patent 
documents were retrieved from Espacenet by the use of a 
choice of several different CPC codes related to the 
development of a chlamydia vaccine. As patent 
applications only become public 18 months after filing 
our results don’t contain the most recent patents 
documents next to the choice to put patents in two 
different patent groups, only for human or veterinary use. 
The design of a search query could have resulted in the 
inclusion- or exclusion of important data or non-relevant 
data, this was addressed by conducting full text analysis 
on all patents. To minimize the degree of affecting our 
data collection, we verified the search criteria with 
experts at the NVO patent offices and the ICTRP 
database and used both free search terms and CPC codes.  
Looking from the perspective of the vaccine innovation 
cycle we show extensive efforts of solving the barriers 
for the chlamydia vaccine development.14,40 In the last 70 
years medical unmet needs are prioritised extensively.22 
Until recently the most difficult barrier to overcome was 
the lack of knowledge on the immune mechanism in 
response to infection with the chlamydia bacteria.22 
Recent tools concerning the construction of the vaccine 
antigen and discovery of the double vaccination route, 
have led to a better understanding of the mechanism of 
immune system overcoming the barrier of transition into 
clinical and business development.6,10,33 
Overall, this study shows the underdeveloped chlamydia 
vaccine market, with no present commercially available 
vaccine for human use with recently one potential 
vaccine candidate for a C. trachomatis vaccine in stage 1 
clinical trials.  
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